Artelo Biosciences Inc (NASDAQ:ARTL) — Market Cap & Net Worth
Market Cap & Net Worth: Artelo Biosciences Inc (ARTL)
Artelo Biosciences Inc (NASDAQ:ARTL) has a market capitalization of $2.60 Million ($2.60 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29668 globally and #5981 in its home market, demonstrating a -3.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Artelo Biosciences Inc's stock price $1.29 by its total outstanding shares 2018746 (2.02 Million). Review ARTL total debt and obligations to assess the company's total debt and financial obligations.
Artelo Biosciences Inc Market Cap History: 2017 to 2026
Artelo Biosciences Inc's market capitalization history from 2017 to 2026. Data shows change from $242.25 Million to $2.60 Million (-36.04% CAGR).
Index Memberships
Artelo Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #879 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2792 of 3165 |
Weight: Artelo Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Artelo Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Artelo Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ARTL by Market Capitalization
Companies near Artelo Biosciences Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Artelo Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Artelo Biosciences Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Artelo Biosciences Inc's market cap moved from $242.25 Million to $ 2.60 Million, with a yearly change of -36.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.60 Million | +5.74% |
| 2025 | $2.46 Million | +15.09% |
| 2024 | $2.14 Million | -24.29% |
| 2023 | $2.83 Million | -51.56% |
| 2022 | $5.83 Million | -62.88% |
| 2021 | $15.72 Million | -28.90% |
| 2020 | $22.11 Million | -72.96% |
| 2019 | $81.76 Million | -70.65% |
| 2018 | $278.59 Million | +15.00% |
| 2017 | $242.25 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Artelo Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.60 Million USD |
| MoneyControl | $2.60 Million USD |
| MarketWatch | $2.60 Million USD |
| marketcap.company | $2.60 Million USD |
| Reuters | $2.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more